<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">systhiper</journal-id><journal-title-group><journal-title xml:lang="ru">Системные гипертензии</journal-title><trans-title-group xml:lang="en"><trans-title>Systemic Hypertension</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2075-082X</issn><issn pub-type="epub">2542-2189</issn><publisher><publisher-name>LLC «ИнтерМедсервис»</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">systhiper-115</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ARTICLES</subject></subj-group></article-categories><title-group><article-title>Эффективность и переносимость фозиноприла у больных артериальной гипертонией</article-title><trans-title-group xml:lang="en"><trans-title></trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Морозова</surname><given-names>Т. Е.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андрущишина</surname><given-names>Т. Б.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>ГОУ ВПО Московская медицинская академия им. И.М.Сеченова</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>23</day><month>12</month><year>2022</year></pub-date><volume>5</volume><issue>1</issue><fpage>16</fpage><lpage>19</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Морозова Т.Е., Андрущишина Т.Б., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Морозова Т.Е., Андрущишина Т.Б.</copyright-holder><copyright-holder xml:lang="en">Морозова Т.Е., Андрущишина Т.Б.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.syst-hypertension.ru/jour/article/view/115">https://www.syst-hypertension.ru/jour/article/view/115</self-uri></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Фармакотерапия хронических сердечно-сосудистых заболеваний. Руководство для врачей. Под ред. акад. РАМН Л.И.Ольбинской. М.: Медицина, 2006.</mixed-citation><mixed-citation xml:lang="en">Фармакотерапия хронических сердечно-сосудистых заболеваний. Руководство для врачей. Под ред. акад. РАМН Л.И.Ольбинской. М.: Медицина, 2006.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. European Heart Jour 2004; 25: 1454-70.</mixed-citation><mixed-citation xml:lang="en">Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. European Heart Jour 2004; 25: 1454-70.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Vetter W. Treatment of senile hypertension. The Fosinopril in old patients study (FOPS). Am J Hypertension 1997; 10: 255S-61S.</mixed-citation><mixed-citation xml:lang="en">Vetter W. Treatment of senile hypertension. The Fosinopril in old patients study (FOPS). Am J Hypertension 1997; 10: 255S-61S.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid alherosclerosis: principal results of PHYLLIS-a randomized double-blind trial. Stroke 2004; 35 (12): 2807-12.</mixed-citation><mixed-citation xml:lang="en">Zanchetti A, Crepaldi G, Bond MG et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid alherosclerosis: principal results of PHYLLIS-a randomized double-blind trial. Stroke 2004; 35 (12): 2807-12.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Asselbergs FW, Diercks GF, Hillege HL et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110 (18): 2809-16.</mixed-citation><mixed-citation xml:lang="en">Asselbergs FW, Diercks GF, Hillege HL et al. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110 (18): 2809-16.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект ТРИ Ф (ФЛАГ, ФАСОН, ФАГОТ). Сердечная недостаточность. 2003; 4 (5).</mixed-citation><mixed-citation xml:lang="en">Карпов Ю.А., Мареев В.Ю., Чазова И.Е. Российские программы оценки эффективности лечения фозиноприлом больных с артериальной гипертонией и сердечной недостаточностью. Проект ТРИ Ф (ФЛАГ, ФАСОН, ФАГОТ). Сердечная недостаточность. 2003; 4 (5).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Berdah J, Guest M, Salvador M. Study of the efficacy and safety of fosinopril in general practice in 19,435 hypertensive patients (FLIGHT Study). Am J Cardiol 1998; 82: 15-9.</mixed-citation><mixed-citation xml:lang="en">Berdah J, Guest M, Salvador M. Study of the efficacy and safety of fosinopril in general practice in 19,435 hypertensive patients (FLIGHT Study). Am J Cardiol 1998; 82: 15-9.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tatti P, Pahor M, Byington RP et al. Outcome results of the fosinipril vs amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.</mixed-citation><mixed-citation xml:lang="en">Tatti P, Pahor M, Byington RP et al. Outcome results of the fosinipril vs amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21: 597-603.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
